Incidence and Predictors of Hypertension Among HIV Patients Receiving ART at Public Health Facilities, Northwest Ethiopia: A One-Year Multicenter Prospective Follow-Up Study.
Ethiopia
HIV/AIDS
anti-retroviral therapy
hypertension
Journal
HIV/AIDS (Auckland, N.Z.)
ISSN: 1179-1373
Titre abrégé: HIV AIDS (Auckl)
Pays: New Zealand
ID NLM: 101515943
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
07
2021
accepted:
26
08
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
17
9
2021
Statut:
epublish
Résumé
The introduction of highly active retroviral therapy has dramatically reduced mortality and improved survival among HIV patients. However, there is a possible risk of comorbid complications such as hypertension. Little evidence is available regarding the incidence of hypertension among HIV patients receiving anti-retroviral therapy in Ethiopia. To assess the incidence and predictors of hypertension among HIV positive patients receiving ART at Public Health Facilities, Northwest Ethiopia. A one-year prospective follow-up study was conducted among a cohort of 302 new adult individuals initiating on a standard anti-retroviral therapy regimen with a median (IQR) age of 35 years (IQR=30-41). A pretested data extraction checklist was used to extract baseline patient records. The collected data were entered into Epi-Data version 3.1 and exported to STATA version 14 for analysis. The incidence rate was calculated, and a Kaplan-Meier survival curve was used to estimate the survival probabilities of developing hypertension. Cox proportional hazards model was fitted to identify the predictors of hypertension. About 40 (13.25) new hypertensive cases were observed during the follow-up period, and the remaining 262 (86.75%) were censored. The overall incidence rate of hypertension was 16.35 per 1000 person-month with 2447 patient-month observations. Male sex (AHR = 2.45, 95% CI: 1.02, 6.14), old age (AHR = 2.83, 95% CI: 1.08, 7.45), high BMI (AHR = 6.54, 95% CI: 2.03, 21.13), diabetic comorbidity (AHR = 2.36, 95% CI: 1.07, 5.22), and patients who were on Zidovudine (AZT)-based ART regimen (AHR =3.47, 95% CI: 1.10, 10.94) were significant predictors for the development of hypertension. The findings of this study revealed that incident hypertension is a common problem among HIV patients receiving ART. Routine monitoring of blood pressure and screening and treating high blood pressure should be an integral part of follow-up for HIV patients in ART clinics.
Sections du résumé
BACKGROUND
BACKGROUND
The introduction of highly active retroviral therapy has dramatically reduced mortality and improved survival among HIV patients. However, there is a possible risk of comorbid complications such as hypertension. Little evidence is available regarding the incidence of hypertension among HIV patients receiving anti-retroviral therapy in Ethiopia.
PURPOSE
OBJECTIVE
To assess the incidence and predictors of hypertension among HIV positive patients receiving ART at Public Health Facilities, Northwest Ethiopia.
PATIENTS AND METHODS
METHODS
A one-year prospective follow-up study was conducted among a cohort of 302 new adult individuals initiating on a standard anti-retroviral therapy regimen with a median (IQR) age of 35 years (IQR=30-41). A pretested data extraction checklist was used to extract baseline patient records. The collected data were entered into Epi-Data version 3.1 and exported to STATA version 14 for analysis. The incidence rate was calculated, and a Kaplan-Meier survival curve was used to estimate the survival probabilities of developing hypertension. Cox proportional hazards model was fitted to identify the predictors of hypertension.
RESULTS
RESULTS
About 40 (13.25) new hypertensive cases were observed during the follow-up period, and the remaining 262 (86.75%) were censored. The overall incidence rate of hypertension was 16.35 per 1000 person-month with 2447 patient-month observations. Male sex (AHR = 2.45, 95% CI: 1.02, 6.14), old age (AHR = 2.83, 95% CI: 1.08, 7.45), high BMI (AHR = 6.54, 95% CI: 2.03, 21.13), diabetic comorbidity (AHR = 2.36, 95% CI: 1.07, 5.22), and patients who were on Zidovudine (AZT)-based ART regimen (AHR =3.47, 95% CI: 1.10, 10.94) were significant predictors for the development of hypertension.
CONCLUSION
CONCLUSIONS
The findings of this study revealed that incident hypertension is a common problem among HIV patients receiving ART. Routine monitoring of blood pressure and screening and treating high blood pressure should be an integral part of follow-up for HIV patients in ART clinics.
Identifiants
pubmed: 34526825
doi: 10.2147/HIV.S329838
pii: 329838
pmc: PMC8435532
doi:
Types de publication
Journal Article
Langues
eng
Pagination
889-901Informations de copyright
© 2021 Mulugeta et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests in this work.
Références
PLoS One. 2017 Mar 8;12(3):e0172089
pubmed: 28273105
Circulation. 2008 Jul 8;118(2):e54-60
pubmed: 18566315
Braz J Infect Dis. 2010 Mar-Apr;14(2):158-66
pubmed: 20563442
Lancet. 2010 Aug 14;376(9740):532-9
pubmed: 20638713
Antivir Ther. 2005;10(7):811-23
pubmed: 16315369
Pan Afr Med J. 2019 Jun 06;33:87
pubmed: 31489065
Hypertension. 1992 May;19(5):403-18
pubmed: 1568757
Trop Med Int Health. 2000 Jul;5(7):A3-9
pubmed: 10964276
J Int Assoc Provid AIDS Care. 2013 Sep-Oct;12(5):325-33
pubmed: 23764503
Clin Infect Dis. 2017 Feb 15;64(4):459-467
pubmed: 28172581
J Hypertens. 2003 Jul;21(7):1377-82
pubmed: 12817187
AIDS Rev. 2015 Apr-Jun;17(2):83-95
pubmed: 26035166
PLoS Med. 2018 Mar 7;15(3):e1002523
pubmed: 29513674
BMC Cardiovasc Disord. 2012 Nov 28;12:114
pubmed: 23190867
J Cardiovasc Pharmacol. 1989;13 Suppl 1:S4-10
pubmed: 2468976
Antivir Ther. 2011;16(5):639-45
pubmed: 21817185
Circulation. 1985 Feb;71(2):202-10
pubmed: 3965165
HIV Med. 2006 Jan;7(1):10-5
pubmed: 16313287
J Hypertens. 2013 Jul;31(7):1372-8; discussion 1378
pubmed: 23615323
Br Med Bull. 2001;58:7-18
pubmed: 11714621
Braz J Infect Dis. 2010 May-Jun;14(3):281-7
pubmed: 20835513
Pan Afr Med J. 2012;13:43
pubmed: 23330034
Nature. 2001 Apr 19;410(6831):968-73
pubmed: 11309626
BMC Public Health. 2020 Jun 1;20(1):834
pubmed: 32487185
Int J Epidemiol. 2013 Feb;42(1):221-7
pubmed: 23064501
Cardiovasc Res. 2003 Oct 15;60(1):147-55
pubmed: 14522417
BMC Infect Dis. 2019 May 6;19(1):383
pubmed: 31060507
Curr Atheroscler Rep. 2017 May;19(5):20
pubmed: 28315199
J Hypertens. 2015 Oct;33(10):2039-45
pubmed: 26431192
Circulation. 2008 Jul 8;118(2):e29-35
pubmed: 18566319
Ann Intern Med. 2006 Sep 19;145(6):397-406
pubmed: 16983127
Biodemography Soc Biol. 2015;61(1):1-17
pubmed: 25879259
J Infect Dis. 2012 Jun;205 Suppl 3:S375-82
pubmed: 22577211
PLoS One. 2018 Oct 3;13(10):e0204020
pubmed: 30281618
Yonsei Med J. 2018 Dec;59(10):1245-1252
pubmed: 30450860
J Am Coll Cardiol. 2009 Sep 22;54(13):1185-8
pubmed: 19761941
Clin Infect Dis. 2014 Dec 15;59(12):1787-97
pubmed: 25182245